Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay

Journal of Immunological Methods

Volumn 237, Issue 1-2, 2000, Pages 51-64

  Pospisilova S ^a   Brazda V ^b   Amrichova J ^a   Kamermeierova R ^a   Palecek E ^b   Vojtesek B ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

C terminal; Epitopes; Monoclonal antibodies; p53; PKC phosphorylation

Indexed keywords

CASEIN KINASE II; EPITOPE; MONOCLONAL ANTIBODY; PROTEIN KINASE C; PROTEIN P53;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CANCER CELL; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BASE SEQUENCE; CELL LINE, TRANSFORMED; DNA; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENES, P53; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE C; RATS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0041316513     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00246-X     Document Type: Article

References (47)

1. Agarwal M., Agarwal A., Taylor W., Stark G. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA. 92:1995;8493.
2. Bargonnetti J., Manfredi J.J., Chen X., Marshak D.R., Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:1993;2565.
3. Bartek J., Bartkova J., Lukas J., Staskova Z., Vojtesek B., Lane D.P. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J. Pathol. 169:1993;27.
4. Caron de Fromentel C., Gruel N., Venot C., Debussche L., Conseiller E., Dureuil Ch., Teillaud J., Tocque B., Bracco L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene. 18:1999;551.
5. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.J. Thymocyte apoptosis induced by p53 dependent and independent pathways. Nature. 362:1993;849.
6. Clore G.M., Ernst J., Clubb R., Omichinski J.G., Kennedy W.M., Sakaguchi K., Appella E., Gronenborn A.M. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. 2:1995;321.
7. Dolezalova H., Vojtesek B., Kovarik J. Epitope analysis of the human p53 tumour suppressor protein. Folia Biol. (Praha). 43:1997;49.
8. Dowell S.P., Wilson P.O., Derias N.W., Lane D.P., Hall P.A. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 54:1994;2914.
9. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1:1992;45.
10. Fields S., Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046.
11. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595.
12. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T.D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA. 95:1998;5166.
13. Halazonetis T.D., Kandil A.N. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:1993;5057.
14. Halazonetis T.D., Davis L.J., Kandil A.N. Wild-type p53 adopts a mutant-like conformation when bound to DNA. EMBO J. 12:1993;1021.
15. Harlow E., Lane D.P. Antibodies: A Laboratory Manual. 1988;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
16. Harlow E., Crawford L.V., Pim D.C., Williamson N.M. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39:1981;861.
17. Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R., Harris C.C. Somatic point mutations in the p53 gene of human tumours and cell lines: updated compilation. Nucl. Acids Res. 24:1996;141.
18. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:1994;865.
19. Hupp T.R., Lane D.P. Two distinct signalling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem. 270:1995;18165.
20. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875.
21. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucl. Acids Res. 21:1993;3167.
22. Hupp T.R., Sparks A., Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:1995;237.
23. Jannot C.B., Hynes N.E. Characterization of scFv-421, a single-chain antibody targeted to p53. Biochem. Biophys. Res. Commun. 230:1997;242.
24. Jeffrey P.D., Gorina S., Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498.
25. Kim E., Albrechtsen N., Deppert W. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene. 7:1997;857.
26. Legros Y., Meyer A., Ory K., Soussi T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene. 9:1994;3689.
27. Legros Y., Lafon C., Soussi T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene. 9:1994;2071.
28. Lin J.Y., Chen J.D., Elenbaas B., Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1994;1235.
29. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847.
30. Midgley C.A., Fisher C.J., Bartek J., Vojtesek B., Lane D., Barnes D.M. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci. 101:1992;183.
31. Milner J. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature. 310:1984;143.
32. Milner J., Cook A. The cellular tumour antigen p53: evidence for transformation-related, immunological variants of p53. Virology. 154:1986;21.
33. Niewolik D., Vojtesek B., Kovarik J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene. 10:1995;881.
34. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80.
35. Palecek E., Vlk D., Stankova V., Brazda V., Vojtesek B., Hupp T.R., Schaper A., Jovin T.M. Tumor suppressor protein p53 binds preferentially to supercoiled DNA. Oncogene. 15:1997;2201.
36. Palecek E., Brazdova M., Cernocka H., Vlk D., Brazda V., Vojtesek B. Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments. Oncogene. 18:1999;3617.
37. Pavletich N.P., Chambers K.A., Pabo C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:1993;2556.
38. Pietenpol J.A., Tokino T., Thiagalingam S., El-Deiry W.S., Kinzler K.W., Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA. 91:1994;1998.
39. Ragimov N., Krauskopf A., Navot N., Rotter V., Oren M. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene. 8:1993;1183.
40. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning. A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press.
41. Selivanova G., Iotsova V., Okan I., Fritsche M., Strom M., Groner B., Grafstrom R.C., Wiman K.G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 6:1997;632.
42. Stephen C.W., Helminen P., Lane D.P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J. Mol. Biol. 248:1995;58.
43. Ullrich S.J., Mercer W.E., Appella E. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene. 7:1992;1635.
44. Vojtesek B., Bartek J., Midgley C.A., Lane D.P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 151:1992;237.
45. Vojtesek B., Dolezalova H., Lauerova L., Svitakova M., Havlis P., Kovarik J., Midgley C.A., Lane D.P. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene. 10:1995;389.
46. Wang Y., Reed M., Wang P., Stenger J.E., Mayr G., Anderson M.E., Schwedes J.F., Tegtmeyer P. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 12B:1993;2575.
47. Yewdell J.W., Gannon J.V., Lane D.P. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:1986;444.